ThirdWave Obtains FDA Clearance for Proprietary Molecular Test
This is the second time the NASDAQ-traded company Third Wave Technologies has received FDA clearance for its molecular testing products. The company’s InPlex™ CF Molecular Test can both detect and identify cystic fibrosis mutations in a patient’s DNA samples. The microfluidic card used for this test was co-developed with the 3M Company. According to the company’s research of the Cystic Fibrosis Foundation, cystic fibrosis affects more than 30,000 Americans every year, and is the most commonly-inherited disease in the US.
↑ Back to Nano World Breaking News™
Nano World News™ Issue Archive:
RSS feed